What Does NRx Pharmaceuticals' Recent $22.3 Million Offering Mean for Investors

Related Articles

What Does Hitek Global's Recent $8 Million Offering Mean for Investors

6 days ago

What Does Getty Realty's $131 Million Stock Offering Mean for Investors

3 months ago

What Does BriaCell's Latest Offering Mean for Investors

1 week ago

What Does EPRT's Latest Debt Offering Mean for Investors

6 days ago

Category

You may also like

Stock News•1 week ago

NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

NRx Pharmaceuticals priced a public offering of 5.71M shares of common stock at $3.50 per share. The offering aims to raise capital for the clinical-stage biopharmaceutical company, though the total g...

NRXP

Share

Stock News•3 weeks ago

NRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market Uncertainty

NRx Pharmaceuticals was downgraded to 'Sell' following clinical trial failures for ZYESAMI and NRX-101. While KETAFREE and NRX-100 programs remain active, the company faces significant regulatory and ...

NRXP

Share

Stock News•3 weeks ago

NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

NRx Pharmaceuticals (NRXP) will report Q1 earnings on May 18, with analysts projecting $19.43M in revenue and a loss of $0.11 per share. The company recently secured FDA clearance for a new clinical t...

NRXP

Share

Stock News•1 months ago

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

CNS Pharmaceuticals raised $22.5 million in a private placement financing from institutional healthcare investors. The company plans to use the proceeds to acquire clinical-stage assets with near-term...

CNS

Share